Overlapping Therapy with High-Dose Tamoxifen and CYP2D6 Inhibitors Modifies Medication Adherence in Breast Cancer Patients

被引：0
|
作者：
Markward, N. J.
Tinnirello, J.
Khalid, M.
Frueh, F. W.
Milayna, S.
Aubert, R. E.
Epstein, R. S.
机构：
[1] Medco Hlth Solut Inc, Bethesda, MD USA
[2] Medco Hlth Solut Inc, Franklin Lakes, NJ USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P4-02-15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-02-15
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment
    Charoenchokthavee, Wanaporn
    Panomvana, Duangchit
    Sriuranpong, Virote
    Areepium, Nutthada
    BREAST CANCER-TARGETS AND THERAPY, 2016, 8 : 149 - 155
  • [32] The effect of CYP 2D6 genotype and CYP2D6 inhibitors on tamoxifen
    Stearns, V
    Hayes, DF
    Jin, Y
    Ullmer, L
    Nguyen, A
    Storniolo, AM
    Flockhart, U
    Desta, Z
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 5S - 5S
  • [33] Can tamoxifen therapy be optimized for patients with breast cancer on the basis of CYP2D6 activity assessments? Commentary
    Takimoto, Chris H.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (03): : 152 - 153
  • [34] Endocrine Therapy: Translational Research on CYP2D6 Genetics for Tamoxifen Response in Breast Cancer
    Branch, H.
    Schroth, W.
    Bacchus, L.
    Simon, W.
    Eichelbaum, M.
    Schwab, M.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 (12) : 1223 - 1224
  • [35] CYP2D6 Polymorphisms and the impact on tamoxifen therapy
    Beverage, Jacob N.
    Sissung, Tristan M.
    Sion, Amy M.
    Danesi, Romano
    Figg, William D.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2007, 96 (09) : 2224 - 2231
  • [36] Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure
    Kiss, Adam
    Menus, Adam
    Toth, Katalin
    Deri, Mate
    Sirok, David
    Gabri, Evelyn
    Belic, Ales
    Csukly, Gabor
    Bitter, Istvan
    Monostory, Katalin
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2020, 270 (01) : 71 - 82
  • [37] Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure
    Ádám Kiss
    Ádám Menus
    Katalin Tóth
    Máté Déri
    Dávid Sirok
    Evelyn Gabri
    Ales Belic
    Gábor Csukly
    István Bitter
    Katalin Monostory
    European Archives of Psychiatry and Clinical Neuroscience, 2020, 270 : 71 - 82
  • [38] CYP2D6 polymorphisms and tamoxifen: therapeutic perspectives in the management of hormonodependent breast cancer patients
    Barriere, J.
    Formento, J. -L.
    Milano, G.
    Ferrero, J. -M.
    BULLETIN DU CANCER, 2010, 97 (03) : 311 - 320
  • [39] CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients
    Sirachainan, Ekaphop
    Jaruhathai, Sureerat
    Trachu, Narumol
    Panvichian, Ravat
    Sirisinha, Thitiya
    Ativitavas, Touch
    Ratanatharathorn, Vorachai
    Chamnanphon, Montri
    Sukasem, Chonlaphat
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2012, 5 : 149 - 153
  • [40] Impact of CYP2D6 polymorphisms on adverse events in patients with breast cancer treated with tamoxifen: Insights from an early dose escalation trial in CYP2D6 poor metabolizers
    Blancas, Isabel
    Martinez-De Duenas, Eduardo
    Rodriguez-Serrano, Fernando
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345